SK Bioscience, which developed Korea´s first COVID-19 vaccine, SKYCovione, said Thursday that the biotech company aims to address the issue of vaccine inequality by intensifying collaboration with international organizations so that people living in low-income countries will be easily able to prevent life-threatening diseases.